Last updated on August 2020

Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy


Brief description of study

Non Small Cell Lung Cancer (NSCLC) remains the leading cause of death by cancer in the world. Because of the increase in lung cancer incidence with age and the increase of life expectancy, about half of the patients are patients aged 70 or older. Several clinical trials have shown the interest of adding immunotherapy to standard 1st line chemotherapy in NSCLC. Although in these studies there was not necessarily a higher age limit, in fact the proportion of included patients aged 75 or older remains low (between 7 and 10%). It is therefore necessary to conduct a trial dedicated to these patients in order to determine whether immunotherapy is as effective and tolerated as in the general population.

Clinical Study Identifier: NCT03977194

Find a site near you

Start Over

Aix-en-Provence - CH

Aix-en-Provence, France
  Connect »

Avignon - CH

Avignon, France
  Connect »

Besan on - CHU

Besançon, France
  Connect »

M con - CH

Mâcon, France
  Connect »

Lyon - URCOT

Pierre-Bénite, France
  Connect »

Saint-Etienne - CHU

Saint-Étienne, France
  Connect »

Besan on - CHU

Besançon, France
  Connect »

M con - CH

Mâcon, France
  Connect »

Lyon - URCOT

Pierre-Bénite, France
  Connect »

Saint-Etienne - CHU

Saint-Étienne, France
  Connect »

Besan on - CHU

Besançon, France
  Connect »

M con - CH

Mâcon, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.